Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective.
Mistry R, May JR, Suri G, Young K, Brixner D, Oderda G, Biskupiak J, Tang D, Bhattacharyya S, Mishra D, Bhattacharyya D, Dalal AA.
Mistry R, et al. Among authors: bhattacharyya d, bhattacharyya s.
J Manag Care Spec Pharm. 2018 Jun;24(6):514-523. doi: 10.18553/jmcp.2018.24.6.514.
J Manag Care Spec Pharm. 2018.
PMID: 29799329
Free PMC article.
BACKGROUND: U.S. regulatory approvals of the cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitors ribociclib and palbociclib as add-ons to letrozole greatly enhance the prospects for treating postmenopausal women with hormone receptor-positive (HR+)/human epidermal recepto …
BACKGROUND: U.S. regulatory approvals of the cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitors ribociclib and palbociclib as add-o …